<DOC>
	<DOCNO>NCT00000994</DOCNO>
	<brief_summary>To determine whether take zidovudine ( AZT ) change natural course HIV infection patient AIDS-associated Kaposi 's sarcoma ( KS ) whether administer AZT similar dose different interval reduce toxicity manageable treatment plan . Patients infected AIDS benefit therapy effective anti-AIDS virus agent . AZT drug effective inhibiting effect HIV infection . The study show whether toxicity AZT reduce manageable treatment plan , whether AZT therapy delay development opportunistic infection and/or KS lesion .</brief_summary>
	<brief_title>A Study AZT HIV-Infected Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>Patients infected AIDS benefit therapy effective anti-AIDS virus agent . AZT drug effective inhibiting effect HIV infection . The study show whether toxicity AZT reduce manageable treatment plan , whether AZT therapy delay development opportunistic infection and/or KS lesion . Patients divide two treatment group , first receive AZT 5 dos day , second receive AZT 3 dos per day . A placebo group divide two match two treatment group . Study patient stratify accord whether ( ) 10 few cutaneous lesion without oral lesion ( b ) extensive cutaneous lesion oral lesion . Patients see outpatient basis weekly first 2 month , every week next 2 month , monthly thereafter .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Acute treatment mucocutaneous candidiasis , localize cutaneous herpes simplex , localize disseminated zoster infection . Concurrent Treatment : Allowed : Blood transfusion treatment Grade 3 hemoglobin toxicity patient 's cardiovascular status compromise hemoglobin fails show sign recovery follow withdrawal study drug . Toxicity grade accord NIAID Recommendations Grading Acute Subacute Toxic Effects ( Adults ) . Patients must : HIVrelated , biopsyproven Kaposi 's sarcoma mucocutaneous lesion without constitutional symptom . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Symptomatic , visceral Kaposi 's sarcoma . Lymphedema . HIV neurologic disease determine standard neurologic examination neuropsychological questionnaire . Concurrent Medication : Excluded : Aspirin acetaminophen regular basis longer 72 hour without approval investigator . Cimetidine . Flurazepam . Indomethacin . Ranitidine . Probenecid . Drugs cause anemia , neutropenia , significant risk nephrotoxicity . Prophylaxis chronic suppression herpes simplex . Treatment herpes simplex virus cutaneous disease often month 5 7 day . Concurrent Treatment : Excluded : Radiation therapy treatment Kaposi 's sarcoma lesion . The following patient exclude study : Patients history AIDSdefining opportunistic infection . Patients follow constitutional symptom etiology establish : Temperature 38 degree and/or drench night sweat 1 month ; watery diarrhea 2 week ; weight loss 10 percent . Patients history systemic malignancy lymphomas . Prior Medication : Excluded : Systemic antineoplastic chemotherapy . Zidovudine ( AZT ) . Excluded within 30 day study entry : Antiretroviral agent . Immunomodulating agent . Prophylaxis Pneumocystis carinii pneumonia . Prophylaxis herpes simplex virus infection . Any experimental therapy . Prior Treatment : Excluded within 30 day study entry : Any experimental therapy . Active substance abuse .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>